Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ziyi Xu, Xuezhi Hao, Qi Wang, Jing Wang, Ke Yang, Shouzheng Wang, Fei Teng, Junling Li & Puyuan Xing. (2022) Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer Management and Research 14, pages 863-873.
Read now
Read now
Sofia Lampaki, Giannis Mountzios, Vassilis Georgoulias, Aggeliki Rapti, Ioannis Xanthakis, Sofia Baka, Dimitrios Mavroudis, Epaminondas Samantas, Elias Athanasiadis, Flora Zagouri, Andriani Charpidou, Alvertos Somarakis, Christina Papista, Aristeidis Nikolaou, Eleftheria Anastasopoulou, Zoe Paparepa & Konstantinos N Syrigos. (2022) Real-world Management Patterns in EGFR-mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece. Future Oncology 18:28, pages 3151-3164.
Read now
Read now
Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra, Daniela Scattolin, Stefano Indraccolo, Stefano Frega, Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, PierFranco Conte & Giulia Pasello. (2021) Real-World Data on Treatment Outcomes in EGFR-Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology 17:19, pages 2513-2527.
Read now
Read now
Fumio Imamura, Madoka Kimura, Yukihiro Yano, Masahide Mori, Hidekazu Suzuki, Tomonori Hirashima, Shouichi Ihara, Kiyoshi Komuta, Takayuki Shiroyama, Izumi Nagatomo & Toru Kumagai. (2020) Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation. Future Oncology 16:21, pages 1537-1546.
Read now
Read now
Articles from other publishers (11)
Ard van Veelen, G. D. Marijn Veerman, Marjon V. Verschueren, Judith L. Gulikers, Christi M. J. Steendam, Anita J. W. M. Brouns, Safiye Dursun, Marthe S. Paats, Vivianne C. G. Tjan‐Heijnen, Cor van der Leest, Anne‐Marie C. Dingemans, Ron H. J. Mathijssen, Ewoudt M. W. van de Garde, Patrick Souverein, Johanna H. M. Driessen, Lizza E. L. Hendriks, Robin M. J. M. van Geel & Sander Croes. (2023)
Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with
EGFR
mutated non‐small cell lung cancer
. International Journal of Cancer 154:2, pages 332-342.
Crossref
Crossref
Zeeshan Tariq & McKenna Blyly. (2023) A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non–Small-Cell Lung Cancer After Progression on Erlotinib. American Journal of Therapeutics 30:5, pages e463-e465.
Crossref
Crossref
Sanjay Popat, Myung-Ju Ahn, Simon Ekman, Natasha B. Leighl, Suresh S. Ramalingam, Thanyanan Reungwetwattana, Shankar Siva, Masahiro Tsuboi, Yi-Long Wu & James Chih-Hsin Yang. (2023) Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies. Targeted Oncology 18:1, pages 9-24.
Crossref
Crossref
Xiao-Fang Yi, Jun Song, Ruo-Lin Gao, Li Sun, Zhi-Xuan Wu, Shu-Ling Zhang, Le-Tian Huang, Jie-Tao Ma & Cheng-Bo Han. (2022) Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. Frontiers in Oncology 12.
Crossref
Crossref
Jun Liao, Yihua Huang, Jiadi Gan, Lanlan Pang, Wael A. S. Ali, Yunpeng Yang, Likun Chen, Li Zhang & Wenfeng Fang. (2022) Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status. Cancer Control 29, pages 107327482210813.
Crossref
Crossref
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro & Virginia Calvo. (2021) Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer 21:1.
Crossref
Crossref
Matteo Franchi, Diego Cortinovis & Giovanni Corrao. (2021) Treatment Patterns, Clinical Outcomes and Healthcare Costs of Advanced Non-Small Cell Lung Cancer: A Real-World Evaluation in Italy. Cancers 13:15, pages 3809.
Crossref
Crossref
Jing Liu, Xuemei Li, Yinghong Shao, Xiyun Guo & Jinggui He. (2020) The efficacy and safety of osimertinib in treating nonsmall cell lung cancer. Medicine 99:34, pages e21826.
Crossref
Crossref
Yen-Ting Lin, Tzu-Hsiu Tsai, Shang-Gin Wu, Yi-Nan Liu, Chong-Jen Yu & Jin-Yuan Shih. (2020) Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lung Cancer 145, pages 1-9.
Crossref
Crossref
Takayuki Kishikawa, Takashi Kasai, Masahiko Okada, Ichiro Nakachi, Sayo Soda, Ryo Arai, Ayako Takigami & Masafumi Sata. (2020) Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma. Thoracic Cancer 11:4, pages 935-942.
Crossref
Crossref
. (2019) Osimertinib. Reactions Weekly 1784:1, pages 203-203.
Crossref
Crossref